Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blocking antibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Blocking antibody. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-003678-97 Sponsor Protocol Number: AGO/2011/005 Start Date*: 2011-11-09
    Sponsor Name:Ghent University Hospital
    Full Title: Exploration of TNF-alpha Blockade with golimumab in the Induction of Clinical Remission in Patients with Early peripheral SpondyloArthritis (SpA) according to ASAS-criteria (‘CRESPA’).
    Medical condition: Early stage peripheral Spondyloarthritis (SpA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10056449 Spondyloarthrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000778-20 Sponsor Protocol Number: NOR-202 Start Date*: 2014-07-04
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001306-20 Sponsor Protocol Number: ADVL0815 Start Date*: 2012-03-08
    Sponsor Name:The National Cancer Institute (NCI)
    Full Title: A PHASE I STUDY OF PAZOPANIB AS A SINGLE AGENT FOR CHILDREN WITH RELAPSED OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001419-64 Sponsor Protocol Number: NOR-107 Start Date*: 2014-01-24
    Sponsor Name:Takeda Vaccines (Montana), Inc.
    Full Title: A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuv...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022970-14 Sponsor Protocol Number: CACZ885M2301 Start Date*: 2011-05-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) HU (Prematurely Ended) SE (Prematurely Ended) PL (Completed) LV (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) EE (Completed) GR (Completed) IS (Prematurely Ended) BE (Completed) NO (Completed) CZ (Completed) IT (Completed) BG (Prematurely Ended) SI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001925-15 Sponsor Protocol Number: ISS20159321 Start Date*: 2018-10-22
    Sponsor Name:Alcedis GmbH
    Full Title: Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant me...
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002980-26 Sponsor Protocol Number: CACZ885A2102 Start Date*: 2004-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP...
    Medical condition: Muckle-Wells Syndrome: rare hereditary, autosomal dominant, systemic inflammatory disease, characterized by recurrent episodes of fever, arthralgia, myalgia, urticarial rash, and conjunctivitis. La...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004367-22 Sponsor Protocol Number: CACZ885D2306 Start Date*: 2008-05-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodi...
    Medical condition: The following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064569 Muckle-Wells syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002201-66 Sponsor Protocol Number: CBYM338X2207 Start Date*: 2013-11-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory, randomized, double-blind, placebo-controlled study to investigate the effect of BYM338 on muscle in patients requiring prolonged mechanical ventilation
    Medical condition: Group III failure to wean patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10042613 - Surgical and medical procedures 10067221 Mechanical ventilation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004866-42 Sponsor Protocol Number: AIO KRK 0107 Start Date*: 2009-07-27
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Can...
    Medical condition: Metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024342-30 Sponsor Protocol Number: CBYM338X2202 Start Date*: 2011-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the panc...
    Medical condition: Condition of cachexia in adults with stage IV metastatic non-small cell lung cancer or stage III/IV pancreatic adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004005-40 Sponsor Protocol Number: NL63552.000.17 Start Date*: 2018-02-15
    Sponsor Name:Radboud university medical center
    Full Title: Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model fo...
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10064864 Malaria antibody positive LLT
    20.0 100000004862 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002995-29 Sponsor Protocol Number: CNTO1959PSO3009 Start Date*: 2017-05-10
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
    Medical condition: Moderate to Severe Plaque-Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001379-66 Sponsor Protocol Number: CHMI-trans1 Start Date*: 2016-04-28
    Sponsor Name:Radboud university medical center
    Full Title: Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model fo...
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10070881 Malaria antibody test positive PT
    19.0 100000004862 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016859-22 Sponsor Protocol Number: CACZ885D2307 Start Date*: 2013-02-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younge...
    Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068850 Cryopyrin associated periodic syndrome LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) GB (Completed) BE (Completed) Outside EU/EEA IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000417-44 Sponsor Protocol Number: PHP-OCM-301A Start Date*: 2016-03-31
    Sponsor Name:Delcath Systems, Inc
    Full Title: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma.
    Medical condition: Hepatic-Dominant Ocular Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068117 Metastatic ocular melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000835-30 Sponsor Protocol Number: MONET Start Date*: 2021-10-12
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: RESCUE THERAPY WITH THE HUMAN ANTI-CD38 ANTIBODY MOR202 (FELZARTAMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY WHO FAILED ANTI-CD20 TARGETED THERAPY: A PILOT, PROOF-OF-CONCEPT STUDY
    Medical condition: Membranous Nephropathy who Failed Anti-CD20 Target Therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003582-10 Sponsor Protocol Number: AVANA Start Date*: 2019-01-17
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: PHASE II STUDY OF PREOPERATIVE CHEMORADIOTHERAPY PLUS AVELUMAB IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005455-15 Sponsor Protocol Number: CACZ885D2304 Start Date*: 2007-06-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclona...
    Medical condition: Muckle-Wells Syndrome (Autoinflammatory Disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064569 Muckle-Wells syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:54:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA